September 14, 2023
Damon R. Race, President & CEO
RALEIGH, NC – GeneVentiv Therapeutics, a pre-clinical gene therapy company developing the first universal gene therapy for all types of hemophilia and the first for patients with inhibitors, today was announced winner of the Startup Spotlight pitch competition at BioPharm USA 2023. This year, the BioPharm USA event was held in Raleigh, NC from September 13-14, 2023.
“I am extremely proud to have won the Startup Spotlight pitch competition, especially considering the high-caliber of the companies that participated. The judges recognized the tremendous unmet need for inhibitor patients that our gene therapy addresses,” commented Damon Race, CEO of GeneVentiv Therapeutics.
GeneVentiv’s lead program, GENV-HEM (AAV8.FVa), is the only single infusion, universal, AAV-based gene therapy able to treat all types of hemophilia. Unlike other AAV-based hemophilia gene therapies, GENV-HEM is the only gene therapy able to treat the 33% of hemophilia patients with neutralizing antibodies (inhibitors) to their missing clotting factor. There are 50,000 inhibitor patients in the developed world. Approved, single infusion, gene therapies for non-inhibitor patients are priced between $2.9M and $3.5M. GENV-HEM has received Orphan Drug Designation from the FDA for Hemophilia A and B with or without inhibitors and a Letter of Support from the National Bleeding Disorders Foundation.
About GeneVentiv Therapeutics:
GeneVentiv Therapeutics is a pre-clinical gene therapy company focused on blood disorders. Our lead program, GENV-HEM (AAV8.FVa), is the only single infusion, universal, AAV-based gene therapy able to treat all types of hemophilia. Unlike other AAV-based hemophilia gene therapies, GENV-HEM is the only gene therapy able to treat the 33% of hemophilia patients with neutralizing antibodies (inhibitors) to their missing clotting factor. There are 50,000 inhibitor patients in the developed world. Approved, single infusion, gene therapies for non-inhibitor patients are priced between $2.9M and $3.5M. GENV-HEM has received Orphan Drug Designation from the FDA for Hemophilia A and B with or without inhibitors and a Letter of Support from the National Bleeding Disorders Foundation.